Envoy Medical (COCH) Net Income towards Common Stockholders (2021 - 2026)

Envoy Medical (COCH) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$5.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 8.58% year-over-year to -$5.7 million; the trailing twelve-month figure through Mar 2026 stood at -$28.1 million (down 5.84% YoY), and the FY2025 full-year result was -$28.7 million, down 2.46% from the prior year.
• Net Income towards Common Stockholders grew to -$5.7 million in Q1 2026, from -$7.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $18.0 million in Q2 2022 to a low of -$13.3 million in Q1 2023.
• A 5-year average of -$4.3 million and a median of -$6.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders surged 24184.87% in 2022 and slumped 639.71% in 2024, its largest moves.
• Tracing COCH's Net Income towards Common Stockholders over 5 years: stood at -$11.5 million in 2022, then surged by 45.11% to -$6.3 million in 2023, then slipped by 22.0% to -$7.7 million in 2024, then decreased by 0.66% to -$7.7 million in 2025, then increased by 26.32% to -$5.7 million in 2026.
• Business Quant data shows COCH's Net Income towards Common Stockholders at -$5.7 million in Q1 2026, -$7.7 million in Q4 2025, and -$7.7 million in Q3 2025.